AstraZeneca R&D VP Steve Yang On Building R&D Success In Emerging Markets: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
The global pharma market in the next five years is expected to grow 3-6% compared to 6.2% in the past five years, while emerging markets will drive major growth and will hold 28% of global spending on medicines by 2015.
You may also be interested in...
MNCs Look To China For Fresh R&D Models, Different Approaches
China’s pharma market offers a chance to try out new R&D models and a different approach to doing business, but local partners are required, said speakers during the inaugural Shanghai CEO Conference.
GSK Establishes Discovery Unit For Traditional Chinese Medicine
GSK transforms DPU in Shanghai into TCM discovery unit that will consist of a small number of select scientists with both Western drug discovery experience and TCM knowledge.
Pfizer's Salomon Azoulay And Bing Yan On Prevenar, Partnering In China Post-Lipitor: An Interview With PharmAsia News (Part 2 of 2)
Pfizer Inc. CEO Ian Read recently affirmed Pfizer's commitment to emerging markets, choosing to keep its established products unit in-house even as he looks to divest non-core assets like the animal health and nutrition business units. Just one week after the announcement of Read's plan, Salomon Azoulay, Pfizer's senior VP for medical & development emerging markets, and Pfizer China Vaccines Lead Bing Yan sat down with PharmAsia News' Shanghai Bureau to talk about Pfizer's blockbuster vaccines Prevenar and Prevenar 13 - marketed in the U.S. as Prevnar - in what will be the world's largest vaccines market. Azoulay was in town to explore partnerships in China, a topic he also discusses in this interview, as well as the importance of physician education in emerging markets.